SecBot SecBot
Biotech Drug Report Generated Aug 22, 2026

NovoLog

NVO·NOVO NORDISK A S
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (FDA approvals dating to 2000)
Time to market
Already approved and commercially available since 2000.
Why 3/10
NovoLog was first FDA-approved in 2000 and has no pending PDUFA date, pivotal readout, or regulatory decision scheduled in the next 12 months. As an already-approved, marketed drug at a large-cap pharma company where GLP-1 products now dominate, no hard binary catalyst exists to move NVO shares based on this product alone.
⚠ Few sources Few sources were found for this drug. Treat the rating as low-confidence and verify against the cited sources.
Actionable Insight NEUTRAL

NovoLog is a mature, off-patent insulin with no binary catalysts ahead, not a stock-moving event for a ~$207B market-cap company. Investors should watch biosimilar erosion (Amphastar's I004) and Novo Nordisk's overall diabetes revenue mix shift toward GLP-1s, not NovoLog specifically. If you own NVO, this drug alone is not a thesis driver.

Price Chart

Loading chart...

Executive Summary

NovoLog (insulin aspart) is a rapid-acting insulin analog that was first FDA-approved in 2000 and has been a staple of Novo Nordisk's diabetes portfolio for over 25 years. It is now an off-patent, mature commercial product facing biosimilar competition (Amphastar's I004 biosimilar insulin aspart completed Phase 3). With no upcoming FDA catalysts or pivotal readouts for this drug and Novo Nordisk's business now dominated by GLP-1 blockbusters (Ozempic, Wegovy), NovoLog contributes a diminishing share of the company's value and revenue growth story.

How It Works

NovoLog is a rapid-acting insulin analog, a slightly modified version of natural human insulin that works faster. Patients inject it at mealtimes to control the blood-sugar spike after eating. It replaces or supplements the body's own insulin production in people with diabetes (Type 1 and Type 2).

Trial Status

NovoLog was originally FDA-approved on June 7, 2000 (NovoLog PenFill), followed by NovoLog Mix 70/30 PenFill on November 1, 2001, and NovoLog Mix 50/50 on August 26, 2008. It is widely marketed as a rapid-acting mealtime insulin analog. Biosimilar competitor Amphastar (AMPH) completed Phase 3 trials for its insulin aspart biosimilar (I004) referencing NovoLog.

The Two-Sided Case

▲ Bull Case3
NovoLog is an established brand with decades of real-world use, physician familiarity, and formulary access that creates switching inertia even after patent expiry.
Novo Nordisk's vertically integrated insulin manufacturing scale provides a cost advantage that makes it hard for biosimilar entrants to undercut significantly.
Diabetes prevalence continues to grow globally (~537M adults), providing steady demand tailwinds even if NovoLog's share shrinks.
▼ Bear Case4
Off-patent and facing biosimilar competition: Amphastar's I004 (insulin aspart biosimilar) has completed Phase 3 trials referencing NovoLog, which will likely erode pricing and volume.
Insulin pricing has faced persistent political/market pressure in the U.S., including Medicare Part D redesign and state price-gouging laws compressing margins.
Novo Nordisk's pipeline and commercial focus has shifted sharply toward GLP-1 drugs (Ozempic, Wegovy), which now drive growth, NovoLog is a legacy product with declining strategic importance.
Rapid-acting insulin class faces competition from faster insulins (Fiasp, Lyumjev) and non-injectable alternatives.

Upcoming Catalysts

  • Biosimilar competition: Amphastar's I004 (insulin aspart biosimilar) completed Phase 3, any FDA filing/approval decision could pressure NovoLog pricing and market share.
  • Annual formulary and pricing updates from PBMs and Medicare (Part D) typically in Q3/Q4 each year.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVO NORDISK A S COURT-RULING NVO ·Originating report

Sources · 1

Hover a chip for the title
1 sec.gov